Кардиоревматология: настоящее и будущее. Часть II

Обложка


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

У пациентов, страдающих ревматическими заболеваниями, отмечают существенное нарастание риска формирования и ускоренного прогрессирования кардиоваскулярной патологии, что обусловлено значимой ролью воспалительного процесса как одного из этиологических факторов атерогенеза и хронической сердечной недостаточности. Доказано, что достижение стойкой клинико-лабораторной ремиссии иммуновоспалительного заболевания способствует снижению риска сердечно-сосудистых осложнений. Поскольку хроническое воспаление непосредственно связано с широким перечнем сопутствующих состояний, это необходимо учитывать при планировании и проведении рационального медикаментозного лечения мультиморбидных больных.

Известно, что лекарственные средства, применяемые в ревматологии, обладают разнообразными эффектами на состояние сердечно-сосудистой системы. При этом в последнее десятилетие усилился научный интерес к потенциальной возможности назначения противовоспалительных агентов различных уровней для профилактики, а также лечения атеросклероза и ишемической болезни сердца. Особое внимание уделяют модуляции сигнального пути инфламмасома NLRP3 – интерлейкин-1 – интерлейкин-6 – С-реактивный белок. Его ингибирование, как показано в ряде исследований, может приводить к снижению вероятности возникновения сердечно-сосудистых событий.

В настоящем обзоре представлены современные данные о влиянии противоревматических препаратов различных классов на сердечно-сосудистую систему, включая их потенциальные положительные и неблагоприятные эффекты.

Полный текст

Доступ закрыт

Об авторах

Yi Ma

Третья Сянья больница Центрального Южного Университета

Email: mayi2908@yandex.ru
ORCID iD: 0000-0002-2339-4263

канд. мед. наук

Китай, Чанша

Zhuo Wang

Третья Сянья больница Центрального Южного Университета

Email: wangzhuo1008@yandex.ru
ORCID iD: 0000-0002-2415-4982

канд. мед. наук

Китай, Чанша

Вадим Иванович Мазуров

Северо-Западный государственный медицинский университет им. И.И. Мечникова; Клиническая ревматологическая больница № 25

Email: maz.nwgmu@yandex.ru
ORCID iD: 0000-0002-0797-2051
SPIN-код: 6823-5482

д-р мед наук, профессор, академик РАН, заслуженный деятель науки РФ

Россия, Санкт-Петербург; Санкт-Петербург

Евгений Александрович Трофимов

Северо-Западный государственный медицинский университет им. И.И. Мечникова

Email: evgeniy.trofimov@szgmu.ru
ORCID iD: 0000-0003-3236-4485
SPIN-код: 4358-1663

д-р мед наук

Россия, Санкт-Петербург

Роман Андреевич Башкинов

Северо-Западный государственный медицинский университет им. И.И. Мечникова; Клиническая ревматологическая больница № 25

Автор, ответственный за переписку.
Email: bashkinov-roman@mail.ru
ORCID iD: 0000-0001-9344-1304
SPIN-код: 5169-5066

MD

Россия, 191015, Санкт-Петербург, Кирочная ул., д. 41; Санкт-Петербург

Список литературы

  1. Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130. doi: 10.1016/j.ajpc.2020.100130
  2. Ridker PM. Anticytokine agents: Targeting interleukin signaling pathways for the treatment of atherothrombosis. Circ Res. 2019;124(3):437–450. doi: 10.1161/CIRCRESAHA.118.313129
  3. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20(6):662–668. doi: 10.1097/MNH.0b013e32834ad504
  4. Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19(6):27. doi: 10.1007/s11883-017-0660-3
  5. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–460S. doi: 10.1093/ajcn/83.2.456S
  6. Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12(3):168–176. doi: 10.1038/nrcardio.2014.206
  7. Lutgens E, Atzler D, Döring Y, et al. Immunotherapy for cardiovascular disease. Eur Heart J. 2019;40(48):3937–3946. doi: 10.1093/eurheartj/ehz283
  8. Ridker PM. From C-reactive protein to Interleukin-6 to Interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156. doi: 10.1161/CIRCRESAHA.115.306656
  9. Jin Y, Fu J. Novel insights into the NLRP 3 inflammasome in atherosclerosis. J Am Heart Assoc. 2019;8(12):e012219. doi: 10.1161/JAHA.119.012219
  10. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272
  11. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–1233. doi: 10.1161/CIRCULATIONAHA.115.018381
  12. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182. doi: 10.1016/S0140-6736(09)60447-5
  13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi: 10.1056/NEJMoa0807646
  14. Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–1530. doi: 10.2174/138161212799504803
  15. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147(2):253–261. doi: 10.1016/s0021-9150(99)00193-8
  16. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104(20):2395–2400. doi: 10.1161/hc4501.099312
  17. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522529. doi: 10.1002/acr.20371
  18. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. doi: 10.1016/j.amjcard.2011.06.054
  19. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi: 10.1056/NEJMoa1707914
  20. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. doi: 10.1016/j.jacc.2012.10.027
  21. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847. doi: 10.1056/NEJMoa2021372
  22. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi: 10.1056/NEJMoa1912388
  23. Samuel M, Tardif JC, Bouabdallaoui N, et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776–785. doi: 10.1016/j.cjca.2020.10.006
  24. Casula M, Andreis A, Avondo S, et al. Colchicine for cardiovascular medicine: a systematic review and meta-analysis. Future Cardiol. 2022;18(8):647–659. doi: 10.2217/fca-2020-0206
  25. Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069. doi: 10.1016/S0140-6736(21)00520-1
  26. Wada Y, Jensen C, Meyer ASP, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279–285. doi: 10.1016/j.jjcc.2023.05.006
  27. Mazurov VI, Lesnyak OM, editors. Rheumatology. Pharmacotherapy without errors. Moscow: E-noto; 2017. 528 p. (In Russ.)
  28. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642. doi: 10.1161/CIRCULATIONAHA.106.181424
  29. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93(19):10417–10422. doi: 10.1073/pnas.93.19.10417
  30. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55(3):506–519. doi: 10.1016/s0008-6363(02)00414-5
  31. Leonova MV. Cardiotoxicity of non-steroid anti-inflammatory drugs. Consilium Medicum. 2019;21(10):107–116. EDN: DVVPVO doi: 10.26442/20751753.2019.10.190191
  32. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. doi: 10.1371/journal.pmed.1001098
  33. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. doi: 10.1016/S0140-6736(13)60900-9
  34. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–2235. doi: 10.1161/CIRCULATIONAHA.110.004671
  35. Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574–584. doi: 10.1038/s41569-020-0366-z
  36. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15. doi: 10.1172/JCI27291
  37. Arutyunov GP, Paleev FN, Tarlovskaya EI, et al. Pericarditis. Clinical Guidelines 2022. Russian Journal of Cardiology. 2023;28(3):107–167. EDN: QMPQPU doi: 10.15829/1560-4071-2023-5398
  38. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964. doi: 10.1093/eurheartj/ehv318
  39. Meara AS, Simon LS. Advice from professional societies: appropriate use of NSAIDs. Pain Med. 2013;14 Suppl 1:S3–S10. doi: 10.1111/pme.12282
  40. Verhoeven F, Prati C, Maguin-Gaté K, et al. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):258. doi: 10.1186/s13075-016-1157-0
  41. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. doi: 10.1136/annrheumdis-2014-206624
  42. Deng HW, Mei WY, Xu Q, et al. The role of glucocorticoids in increasing cardiovascular risk. Front Cardiovasc Med. 2023;10:1187100. doi: 10.3389/fcvm.2023.1187100
  43. Atzeni F, Rodríguez-Carrio J, Popa CD, et al. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(5):270–290. doi: 10.1038/s41584-021-00593-3
  44. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331. doi: 10.1136/ard.2009.113696
  45. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28. doi: 10.1136/annrheumdis-2016-209775
  46. Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):136–182. EDN: SWZXVO doi: 10.15829/1560-4071-2021-4790
  47. Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015;12(4):199–211. doi: 10.1038/nrcardio.2015.5
  48. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59(4):308–314. doi: 10.1097/FJC.0b013e318241c385
  49. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295–307. doi: 10.1093/rheumatology/kep366
  50. Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–762. doi: 10.1056/NEJMoa1809798
  51. Deftereos SG, Beerkens FJ, Shah B, et al. colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61–78. doi: 10.1161/CIRCULATIONAHA.121.056171
  52. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–1900. doi: 10.1161/CIRCULATIONAHA.120.050771
  53. Mewton N, Roubille F, Bresson D, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021;144(11):859–869. doi: 10.1161/CIRCULATIONAHA.121.056177
  54. Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–2775. doi: 10.1093/eurheartj/ehab115
  55. Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014;2(2):131–137. doi: 10.1016/j.jchf.2013.11.006
  56. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;2016(1):CD011047. doi: 10.1002/14651858.CD011047.pub2
  57. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):119–249. EDN: EUDWYG doi: 10.15829/1560-4071-2023-5452
  58. Mazurov VI, Bashkinov RA, Gaidukova IZ, Fonturenko AYu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. Russian Medical Inquiry. 2021;29(7):24–30. EDN: EZWQOO
  59. Drapkina OM, Mazurov VI, Martynov AI, et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):77–84. EDN: KRCKAU doi: 10.15829/1728-8800-2023-3564
  60. Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. EDN: HBLVVV doi: 10.38109/2075-082X-2022-1-5-22
  61. Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14. doi: 10.5603/CJ.a2021.0001
  62. Drapkina OM, Mazurov VI, Martynov AI, et al. Consensus statement on the management of patients with asymptomatic hyperuricemia in general medical practice. Cardiovascular Therapy and Prevention. 2024;23(1):89–104. EDN: WXKMIG doi: 10.15829/1728-8800-2024-3737
  63. Kushiyama A, Okubo H, Sakoda H, et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012;32(2):291–298. doi: 10.1161/ATVBAHA.111.234559
  64. Rentoukas E, Tsarouhas K, Tsitsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145(2):257–258. doi: 10.1016/j.ijcard.2009.08.037
  65. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161–2167. doi: 10.1016/S0140-6736(10)60391-1
  66. Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926–932. doi: 10.1016/j.jacc.2012.09.066
  67. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217–226. doi: 10.1111/j.1755-5922.2011.00277.x
  68. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–1205. doi: 10.1016/S0140-6736(22)01657-9
  69. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170(15):1358–1364. doi: 10.1001/archinternmed.2010.198
  70. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–2309. doi: 10.1016/j.jacc.2008.01.068
  71. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763–1771. doi: 10.1161/CIRCULATIONAHA.114.014536
  72. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol. 2009;53(25):2405. doi: 10.1016/j.jacc.2008.07.076
  73. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74(7):1368–1372. doi: 10.1136/annrheumdis-2014-205269
  74. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009;63(9):1327–1333. doi: 10.1111/j.1742-1241.2009.02118.x
  75. Chinese Society of Endocrinology (2020). Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China (2019). Chin J Endocrinol Metab. 2020;36(1):1–13. doi: 10.3760/cma.j.issn.1000-6699.2020.01.001
  76. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):670–675. doi: 10.1136/ard.2006.062497
  77. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2
  78. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594–1602. doi: 10.1161/01.CIR.0000124490.27666.B2
  79. Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289–1299. doi: 10.1161/CIRCULATIONAHA.118.038010
  80. Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017;10(11):e004373. doi: 10.1161/CIRCHEARTFAILURE.117.004373
  81. Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc. 2020;9(5):e014941. doi: 10.1161/JAHA.119.014941
  82. Interleukin-6 receptor mendelian randomisation analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–1224. doi: 10.1016/S0140-6736(12)60110-X
  83. Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–2413. doi: 10.1093/eurheartj/ehw171
  84. Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(4):561–576. doi: 10.1002/acr.23875
  85. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138–e140. doi: 10.1093/cvr/cvab231

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Эко-Вектор, 2025


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.